in 1980 to the destruction of endothelial cells during preparation of the vessels. If care was taken to avoid rubbing of the intimal surface during preparation, the tissue always exhibited relaxation when exposed to acetylcholine. Subsequently, these two scientists demonstrated that the relaxation of blood vessels by acetylcholine required an intact endothelium and it exerted its vasodilator property by causing the release of an unidentified substance. 2 This landmark paper also reported briefly that while acetylcholine was unable to relax anoxic vessel tissue preparations, several substances including sodium nitrite and glyceryl trinitrate still produced good relaxation. The importance of this observation was not immediately appreciated until the nature of the substance, termed endothelium-derived relaxing factor (EDRF), was clarified later. ]
Over the ensuing several years, other investigators, endeavouring to define the nature of EDRF, confirmed the initial observations of Furchgott and Zawadzki. Their techniques involved bioassays in which the effluent of intact endothelium 4.5 or of cultured endothelial cells 6.7 initiated relaxation of target vascular tissue denuded of endothelium.
IDENTIFICATION OF EDRF
Although the existence of EDRF became firmly entrenched, its identity was elusive. Several investigators followed unproductive lines in considering arachidonic acid metabolites 7.8, a compound with a carbonyl group] and the cytochrome P-450 system.·
a. Nitric oxide as EDRF
At the 4th International Symposium on Mechanisms of Vasodilators held in Minnesota in 1986, two independent investigators, Furchgott and Ignarro (and co-workers), proposed that EDRF was NO. 11.12 The basis for each of their proposals was quite different.
In the early 1970s in Furchgott's laboratory, a new research fellow had mistakenly used an acidified solution of saline, instead of saline, to prepare a solution of sodium nitrite to be used in the construction of concentration-relaxation curves for helical strips of rabbit aorta already contracted by noradrenaline in physiological Kreb's solution. The solution of sodium nitrite had been expected to cause persistent relaxation of the muscle but instead, the relaxation which was observed was transient. Chemical conditions implied that the addition of acid to the solution of sodium nitrite formed nitrous acid which in turn formed a substance which caused relaxation of the muscle but which was quickly inactivated on contact with the physiological pH of the Kreb's solution. These observations were not pursued until much later when Furchgott recognised the similarity of the response of the helical strips of rabbit aorta to acidified sodium nitrite solution in his laboratory, to studies in another laboratory in which arterial muscle preparations responded to a factor derived from bovine retractor penis muscle which caused relaxation but which also required acidification. 13 Furchgott retested the response of phenylephrine-contracted rings of aorta to neutral and acidified sodium nitrite solution and observed that the acidified solution caused strong but transient relaxation. The response was observed with both endothelium-containing rings and endothelium-free rings. In contrast, neutral and acidified solutions of glyceryl trinitrate and amyl nitrite caused persistent relaxation. It was these physiological observations and knowledge of the reactions of sodium nitrite (NaNO,) at low pH which were the basis for the proposition that EDRF is NO.]I Acidification of sodium nitrate forms nitrous acid, which decomposes to NO and NO l • Furchgott used another physiological observation in support of the proposition that EDRF is NO and which, later, was to become of great importance to clinicians in the selective management of pulmonary hypertension. He showed that the transient relaxing activity of the acidified nitrite solution, like EDRF, was inhibited by haemoglobin. Haemoglobin had long been known to have a very high affinity for NO 14 and to prevent the NO dependent relaxation of blood vessels. 15 Independently, Ignarro and co-workers also postulated in 1986 that EDRF was NO. 12 Their conclusions were based on similarities of biochemical and pharmacological properties of EDRF and gaseous NO. Using bovine pulmonary artery, they demonstrated a remarkable similarity between acetylcholine and NO in causing relaxation of the arterial smooth muscle, the accumulation of intracellular cyclic guanosine monophosphate (cGMP), and the activation of soluble guanylate cyclase, the enzyme that catalyses the formation of cGMP from guanosine triphosphate (GTP). The soluble guanylate cyclase inhibitor, methylene blue, antagonised the dilation evoked by both acetylcholine and NO while oxyhaemoglobin abolished the effects on cyclic GMP caused by both acetylcholine and NO. On the basis that EDRF probably mediated the responses to acetylcholine and the similarity of activity of acetylcholine and NO, 19narro and co-workers postulated that EDRF was either NO or a closely related radical.
Subsequent investigations provided additional circumstantial evidence that EDRF and NO were similar substances. The effects of the perfusate from bovine pulmonary artery and vein (EDRF) were compared to those of a solution of NO in oxygen-free water on precontracted strips of arterial and venous tissue. 16 Both EDRF and NO were labile (half-life 3-5 sec), inactivated by superoxide anion, stabilised by superoxide dismutase and inhibited by oxyhaemoglobin. Both EDRF and NO induced comparable increases in arterial and venous tissue cyclic GMP which was similarly inhibited by oxyhaemoglobin and by methylene blue. Both EDRF and NO reacted with haemoglobin to form nitrosylhaemoglobin and both similarly promoted the diazotisation of sulfanilic acid and yielded the same product after coupling with N-(l-naphthyl)-ethylenediamine.
An important stage in the verification of EDRF as NO was to determine whether NO, like EDRF, was released from endothelial cells. This was first demonstrated by Palmer and co-workers in 1987.17 They used chemiluminescence detection" to determine the presence of NO. They discovered that NO was released from vascular endothelial cells in amounts sufficient to account for relaxation attributable to EDRF. It also had the same relaxation activity, chemical stability and susceptibility to antagonism by haemoglobin, by superoxide dismutase, as EDRF. Furthermore, its release could be stimulated in a concentration-dependent fashion by bradykinin. Later, in 1988, Kelm and co-workers also demonstrated that NO was released from endothelial cells. 19 They used a spectrophotometric assay based on the rapid oxidation of oxyhaemoglobin to methaemoglobin, to detect NO. They demonstrated that NO was released as a free radical from cultured endothelial cells derived from the porcine thoracic aorta. Moreover, the concentration of NO produced was sufficient to explain the smooth muscle relaxation caused by EDRF and exogenous NO. It was also demonstrated that isolated guinea pig hearts released NO into the coronary effluent. The release of NO was stimulated by bradykinin in a dose-dependent manner and was followed by coronary vasodilation after 5 ± 1 sec. 20 The experiments of Furchgott ", Ignarro 12, 16 and Palmer 17 were staged at a time when a substantial body of knowledge already existed concerning the mode of action of nitrovasodilators. Smooth muscle nitrovasodilators such as nitroprusside, organic nitrates, nitrites and nitroglycerin were known to activate guanylate cyclase and to stimulate the formation of intracellular cyclic GMP. Moreover, it was recognised that nitric oxide was responsible for the effects of this class of vasodilator drugs since all released or formed nitric oxide. 21 Indeed, it had been suggested that these drugs be termed nitrogen oxide (nitric oxide)containing vasodilators rather than direct-acting vasodilators. 22 Their vasodilating effects are inhibited by methylene blue which penetrates cells and inhibits guanylate cyclase activation. These actions of nitrovasodilators, in particular those of NO, are very similar to EDRF. The relaxation of vascular smooth muscle by EDRF is also accompanied by a rise in cyclic GMP" and is antagonised by methylene blue. 24 Because NO and EDRF are indistinguisable and NO is the final effector molecule of nitrovasodilators, NO was termed the "endogenous nitrovasodilator". 25 Indeed, in more recent times it has been demonstrated that the effects of other classes of vasodilators, including angiotensin converting enzyme inhibitors and a prostaglandin (PGD2), are mediated by NO. 26,27
b. NO-Re/easing Compound as EDRF
It is generally accepted that EDRF is NO although Angus and Locks argue that if NO is involved in endothelium-dependent relaxation of blood vessels, it is released as an endogenous nitrogen-oxygen containing compound,28 which presumably dissociates to release NO. Amongst the chemical evidence against EDRF being NO is the observation that EDRF binds to ion-exchange resins whereas NO does not. 6, 29 In addition, the activity of EDRF is able to withstand lyophilization which NO cannot, and EDRF cannot exist in Krebs' solution as a gas. 6 Some comparative biological studies also suggest that EDRF and NO are not identical; EDRF fails to cause relaxation of smooth muscle in the trachea 30 or guinea pig taenia coli muscle in contrast to NO. 31 However, both guinea pig taenia coli and guinea pig trachea have been reported to be poorly responsive to both EDRF and NO compared to other NO-containing compounds like nitroprusside and are therefore claimed not to be valid test tissues . 28 It has been demonstrated that NO is released from organic nitrates like glyceryl trinitrate and nitroprusside with or without the addition of thiol reagents. 32 ,22 It has been suggested that EDRF, like the nitrates, is a NO-releasing compound. Indeed, Griffiths and coworkers provided chemical evidence in 1984 that EDRF contains a carbonyl group at or near its active site. 4 Moreover, in a study of the mechanism of smooth muscle relaxation by nitrogen-containing vasodilators, it was shown that guanylate cyclase from bovine coronary artery was activated by glyceryl trinitrate, isosorbide dinitrates, amyl nitrate, NaN02, nitroprusside and NO, but only in the presence of -SH groups from added thiols. It was proposed that the action of nitrovasodilators was due at least in part to the formation of active, unstable intermediate Snitrosothiols. 34 This suggestion was supported by another study which demonstrated that the vasodilator potency of S-nitrosocysteine resembled more that of EDRF, released from cultured bovine aortic endothelial cells, than that of exogenous NO. J5 Organic nitrates are enzymatically degraded via glutathiono-Stransferase to nitrate and nitrite ions and thiocomplexes. More recently in 1992 it was demonstrated that both authentic NO and EDRF react readily with sulfhydryl-containing proteins, which abound in biological tissues, to form proteins with S-nitrosothiol groups and which retain vasodilator effects. It was suggested that S-nitrosothiol groups in proteins serve as intermediates in the metabolism of NO. 36 The conflict concerning the activator of guanylate cyclase by organic nitrates, whether by NO or by an intermediate, is clarified by the observation that activation of guanylate cyclase by organic nitrates in vitro cannot proceed unless the amino acid cysteine is present. 37 Organic nitrates also react with the amino acid cysteine to form nitrites. 34 It is cysteine, in free or bound form, which is able to stimulate the nonenzymatic metabolism of organic nitrates to release nitric oxide (and nitrites) which in turn activates guanylate cyclase and which ultimately leads to smooth muscle relaxation. 38 The enzymatic decomposition of organic nitrates to nitrite ions in the presence of thiols does not activate guanylate cyclase. Thus, nitrovasodilators, with the exception of nitroprusside which liberates NO directly, are degraded into either nitrites and nitrates or into NO with the latter causing muscle relaxation.
Recognition of the dual degradation pathways of organic nitrates offers one explanation for the longrecognised phenomenon of tolerance to nitrovasodilators. The thio-consuming transformation of organic nitrates into nitrite ions causes a depletion of intracellular cysteine which limits the NO pathway of organic nitrate metabolism. 39 Induction of tolerance by nitroglycerin (glyceryl trinitrate) does not change the rate of nitrite production,40 indicating that 1. TlBBALLS ET AL. enzymatic degration is not impeded during tolerance in contrast to the non-enzymatic degradation to NO. Other mechanisms of tolerance have been advanced. Two different mechanisms of tolerance may exist since coronary strips do not develop tolerance to nitroprusside after tolerance has been established to nitroglycerin. 41 An alternative explanation of tolerance is the down-regulation (decreased responsiveness) of guanylate cyclase as indicated by the reduced formation of cGMP in rat aortic tissue after repeated exposure to nitroglycerin. 42 Rabbit aortic tissue has a diminished ability to release EDRF after stimulation with acetylcholine when it has been chronically exposed to exogenous NO in vivo. This suggests that exogenous NO may down-regulate the biosynthesis of EDRF (NO) by vascular endothelial cells. 42 Discrepancies and conflicting reports of the nature of EDRF may be due to the methods of NO detection. Chemiluminescence and spectrophotometry are not able to distinguish NO from nitrite or nitroso species. Electron paramagnetic resonance (EPR) has been used by several investigators to distinguish NO from EDRF. 43, 44 Deoxyhaemoglobin traps NO to form nitrosylhaemoglobin (NO-Hb) which is readily identifiable with EPR and distinguishable from nitrites and nitrogen-containing compounds. In a bioassay technique using femoral arteries stimulated with acetylcholine and a haemoglobin trap for NO, a characteristic signal of NO-Hb could not be detected for EDRF released from endothelial cells whereas exogenous NO caused relaxation and produced the characteristic EPR signal.
The true nature of EDRF, whether NO or a nitrosocompound, is of importance to clinicians because new therapies to control vascular pressures may arise by mimicking EDRF or by promoting its formation or release from an intermediate. Alternatively, it may be important to inhibit its formation.
SYNTHETIC PATHWAY OF NITRIC OXIDE
The precursor of NO has been identified as Larginine. 4547 The release of NO from cultured aortic endothelial cells is enhanced by L-arginine. Studies with '5N-labelled L-arginine and mass spectrometry suggest that NO is formed from the terminal guanidino nitrogen of L-arginine. Analogues of L-arginine, including D-arginine, are not substrates. Indeed, many L-analogues inhibit NO formation by competitive inhibition. 45 One analogue, NCimonomethyl-L-arginine (L-NMMA) has been used extensively to investigate the role of the L-arginine-NO pathway in the regulation of vascular tone.
The production of NO is controlled by an enzyme, nitric oxide synthase (NOS), which exists in two forms. 1 A constitutive form appears responsible for physiological functions which includes modulation of vasomotor tone by vascular endothelium. The enzyme has been purified from bovine aortic endothelial cells and requires calcium, calmodulin (a calcium-binding protein which activates many enzymes), and other factors for full activity. 4' Its activity may also be increased by non-physiological stimuli; E coli lipopolysaccharide immediately enhanced the release of a NO like factor from bovine aortic endothelial cells. 49 The constitutive form of the enzyme is also present in platelets wherein NO inhibits aggregation 1 and is also found in rat brain 50 where NO mediates the action of a neurotransmitter, glutamate, on cGMP formation. 51 The role of NO in the brain has been recently reviewed. 52 It has been speculated that NO may ultimately be implicated in the mode of action of general anaesthetic agents. 53 Another form of the enzyme, an inducible form, is also found in vascular endothelium and in the immune system. 1 In macrophages, NO synthase is activated by agents such as endotoxic lipopolysaccharide and interferon-T'.54 Activation allows macrophages to attack tumour cells and micro-organisms. NO and NO synthase are also present in neutrophils. 55 The inducible enzyme is not dependent on calcium nor calmodulin, is inhibited by glucocorticoids 56 and promotes the prolonged production of NO. Neither form of the enzyme can use L-NMMA as a substrate.
Recently, a complementary DNA (cDNA) which encodes NOS has been identified in rat brain tissue. It has many recognition sites indicating that the enzyme is regulated by many different factors. 57 cDNA has also been identified and cloned from human vascular endothelium. 5H Nitric oxide synthase has been identified by immunofluorescence techniques in rat and guinea pig cardiac ganglion cells and nerve fibres which innervate the sinoatrial and atrioventricular nodes, the myocardium, coronary arteries and pulmonary vessels,59 suggesting an involvement by NO in neurogenic heart regulation, contractility and vascular tone.
THE CIRCULATION AND NITRIC OXIDE a. Vascular Tone
L-arginine induced endothelium-dependent relaxations of rabbit aorta but L-NMMA produced small endothelium-dependent contractions. 47 Subsequently, it was proposed that L-arginine is the physiological precursor for basal and stimulated generation of NO which causes endotheliumdependent relaxation. In the isolated perfused rabbit heart, L-NMMA inhibited the formation of NO and Anaesthesia and Intensive Care, Vol, 21, Nu, 6, December, 1993 the vasodilator effect of acetylcholine and produced a dose-related sustained increase in coronary perfusion pressure. 60 It was suggested that NO regulates vascular tone and is the mediator of acetylcholine. In the pre-constricted isolated guinea pig heart, perfusion with L-NMMA markedly reduced histamine-induced coronary vasodilation. 61 The effects of L-NMMA are reversed with L-arginine. 60 -61 In anaesthetised guinea pigs, L-NMMA raised arterial blood pressure, an effect which was antagonised by L-arginine. In normotensive animals, acetylcholine reduced blood pressure, an effect which was prolonged by L-arginine and curtailed by L-NMMA. 62 In anaesthetised rabbits, L-NMMA produced a dosedependent long-lasting (15-90 min) increase in mean systemic arterial blood pressure and inhibited the hypotensive action of acetylcholine but not that of glyceryl trinitrate. Again, the effects of L-NMMA were reversed by L-arginine. 63 In conscious rats, L-NMMA caused an increase in systemic blood pressure. 64 The vasoconstriction was observed initially in the mesenteric and carotid circulations within a few minutes with low doses but was observed in the renal, mesenteric, limb and carotid circulations with high doses. An infusion of L-NMMA for six hours in conscious rats caused a sustained increment in blood pressure which had not returned to baseline three hours after cessation of the infusion. 65 Renal flow, but not mesenteric or limb blood flow, returned to baseline within one hour of cessation. In conscious dogs,66 L-NMMA caused a constriction of the coronary circulation and a reduction in flow which was reversed with L-arginine.
Thus, the endothelial L-arginine-NO pathway appears to have an important role in the regulation of basal cardiovascular tone. After production by the endothelial cell, NO diffuses across the abluminal interspace into the smooth muscle cell to activate guanylate cyclase which ultimately causes relaxation and vasodilatation (Figure 1 ). Despite the widespread influence of NO however, there may be differences in the influence of EDRF on different parts of the vasculature.
b. Arteria-Venous Differences
Differences in the endothelium-dependent relaxation have been observed in human arteries and veins. 67 In isolated internal mammary arteries and veins, L-NMMA reduced the contractile response to acetylcholine to a greater degree in the artery than the vein. In contrast, the sensitivity to exogenous NO was greater in the vein. The investigators speculated that arteries released more NO than veins. In human volunteers, L-NMMA infused into the veins on the back of the hand did not cause constriction. 68 In contrast, L-NMMA infused into brachial arteries of human volunteers reduced basal blood flow by 50% and attenuated the usual dilator response of acetylcholine. 69 These observations suggest that under basal conditions, there is a continuous release of NO in the arterial circulation but not the venous. In both veins and arteries, L-NMMA did not influence the vasodilatation induced by glyceryl trinitrate. -0 Differential reactivity in the arterial and venous circulation to L-NMMA has also been observed in the microcirculation of the hamster 7J and of the rabbit." In both cases, L-NMMA constricted arterioles but not venules and in the case of the hamster, arterioles only were dilated by NO. It has been suggested that the difference in the responsiveness between femoral artery and saphenous vein to endothelium-dependent dilators is due more to differences in the ability of their endothelia to release EDRF than due to their inability of their smooth muscle to respond to EDRF. '1 Clinically, it has been recognised for many years that the venous circulation is particularly sensitive to nitrovasodilators such as sodium nitroprusside and glyceryl trinitrate.
c. Local Regulation of Flow
The degree of vasodilatation of vessels may be regulated locally by endothelial cells which respond to local flow and wall stress. In dogs, unilateral augmentation of femoral arterial flow, induced by peripheral vasodilatation or by arteriovenous shunt, elicited dilatation of the ipsilateral but not contralateral femoral artery. '" Vasodilatation was dependent on intact endothelium. In a similar model, induced increases in flow or the introduction of pulsatile flow induced the release of an endothelial-derived relaxing factor. 7< Flow-dependent coronary artery dilatation has been demonstrated in humans; the diameter and flow velocity in the proximal circumflex artery of healthy adults increased after distal injection of papaverine. 76 Local production of NO mediates coronary arterial vasodilatation induced by hypoxia.--
NITRIC OXIDE AND CARDIOVASCULAR DISEASE
It is probable that disorders of NO formation account for abnormalities in vascular reactivity observed in various disease states. Local control of dilatation is lost in arterial disease. The coronary arteries of humans with coronary artery disease do not exhibit flow-induced dilatation. '6 In dogs with coronary artery endothelium damaged by a balloon catheter, spontaneous vasoconstriction and diminished dilator response to nitroglycerin were observed -s while in rats balloon damage induced nitric oxide synthase activity in carotid arteries. 70 The regulatory effect of vascular endothelium has been shown to be impaired in atherosclerotic arteries of animals'" and humans. HI In coronary arteries, this has been shown to be due to decreased basal secretion of NO." The regulatory effect of the vascular epithelium is also impaired in animals and humans with hypertension. 83 . 84 The acetylcholine-induced release of EDRF is blunted in humans with hypertension. K< Disorders of nitric oxide metabolism are implicated in endotoxic shock. The cytotoxic effect of endotoxin is mediated by NO synthesised by an inducible NO synthase. 86 An NO-like factor is released from bovine aortic endothelial cells after exposure to E. coli lipopolysaccharide."' The hypotension caused by endotoxin is associated with increased vascular endothelial synthesis of NO. H7 L-NMMA has been demonstrated to inhibit the hypotension induced in dogs by tumour necrosis factor (TNF), HR a cytokine released from macrophages by bacterial endotoxin. The use of L-NMMA has been demonstrated to ameliorate the haemodynamic changes in rats KO and in rabbits given endotoxin Oil and in two adults with septic shock. 91 L-NMMA may become available commercially as an NO-blocker in the treatment of septic shock. ye However, such therapy would require careful dosage and precise timing. Large doses and early therapy with L-NMMA exacerbated hypotension. SR." L-NMMA inhibited both constitutive and inducible nitric oxide synthase but the activity of the former enzyme was protective early in endotoxaemia. 80 More studies are required to establish the role of NO-blockers in septic shock.
Other hyperdynamic circulatory states, such as in cirrhosis, may also be due to abnormalities of NO metabolism.OJ Methylene blue, which inhibits the production of NO by inactivating guanylate cyclase, 04 increased blood pressure in a patient with liver failure. 9< The hypertension of chronic renal failure may be due to the blocked elimination and accumulation of an endogenous analogue of L-arginine, asymmetrical dimethylarginine. %
NITRIC OXIDE -A NEW THERAPEUTIC AGENT
The discovery of EDRF, its identification as NO and the clarification of its synthesis and mode of action within the cardiovascular system present clinicians with a unique new therapy. If NO is the endogenous vasodilator, why not use it instead of intravenous nitrovasodilators? It could be used as an intravenous solution although control would be too difficult. Nitric oxide, in gaseous form, is a better option. However, potential toxicity should be considered carefully.
The biochemistry of nitric oxide and of its redoxactivated forms is complex and poorly understood 07 Neutral nitric oxide (NO·) forms complexes with metal ions in metal\oproteins, exemplified by haemoglobin and by guanylate cyclase. However many /lnaeSlhcsia and Inlensh.:e Care, Vol. 21, No. 6, December, 1993 iron and sulphur contammg proteins are targets. Nitrosonium (NO +) reactions involve aromatic substitution and addition to bases. Nitroxyl anion (NO -) reacts with metals and thiols and may dimerize to form nitrous oxide.
Inhaled NO is rapidly absorbed into the body98 where it combines with haemoglobin to form nitrosylhaemoglobin (NO-Hb). However, little NO-Hb can be detected in blood,99 most reacts with 0, to form methaemoglobin while the nitrogen is released into the serum as nitrates and nitrites and subsequently appear in the urine. 1 (){)
a. Toxic Effects
Nitric oxide may be a noxious gas. Little is known about the toxicity of NO, but more about its related species, nitrogen dioxide (NO,). Both NO and NO, are higher oxides of nitrogen formed by the reaction of metals with acid solutions of nitrates or nitrites or formed by combustion at high temperature. NO and NO, are found in high concentration in cigarette smoke and are inhaled in concentrations of 400-1000 ppm. 10 ) NO is a labile species and a free radicle which can react with oxygen to form NO, which exists in equilibrium with dinitrogen trioxide (N,03) and dinitrogen tetraoxide (N,04)' Contamination of preparations of NO by NO, is a major concern.
Higher oxides of nitrogen have from time to time contaminated preparations of nitrous oxide destined for anaesthetic use. 101 Subsequent experiments with dogs revealed that very high concentrations (0.5-2.0070, 5000-20,000 ppm) of pure nitrogen dioxide and putative pure nitric oxide were rapidly lethal. )03-105 The mechanism of death was due to gross destruction of lung tissue resulting in pulmonary oedema, haemorrhage and desquamation. In addition, a high percentage (up to 100070) of oxyhaemoglobin was converted to methaemoglobin. The consequences were cyanosis, severe hypoxaemia, acidosis and hypotension. In these experiments however, the purity of the NO preparations was never determined, particularly to exclude contamination with NO,. In some experiments, NO was prepared in 0, or was blended with oxygen on delivery, which formed a visibly evident brown coloured gas, most probably NO,.
Under normoxic conditions the reaction of NO with 0, to form NO, is slow. 106 In one experiment, using the occupational safety and health standard for NO, as 5 ppm, it has been calculated that the limit of NO inhalation in a concentration of 20 ppm in 100070 0, is 12 minutes and in air is 60 minutes. 107 In another experiment, NO mixed with 100070 0, or air to constitute 28 ppm generated 3.2 and 2.2 ppm NO, respectively after 10 minutes. 108 In another, a mixture Anaesthesia and Intensive Care, Vol. 21, No_ 6, December, 1993 of NO 56 ppm with 100070 0, or air generated 11.6 and 2.2 ppm NO, respectively in 10 minutes. 108 The threshold limit values for exposure to NO, in Australia are 5 ppm as a short-term exposure level and 3 ppm as a time weighted average over 8 hours while the time weighted average for NO is 25 ppm. 109 The toxic effects of nitrogen dioxide are due to its oxidising effects. Deleterious effects are detectable in lung tissues. Lipoperoxidation of lung lipids has been detected in rats exposed to a scant amount of nitrogen dioxide (1 ppm) for 4 hours. However, the peroxidative changes did not occur immediately but reached a maximum at 24-48 hours after exposure. 110 In studies of human spirometric lung function, alveolar permeability and of activity of serum glutathione peroxidase (an antioxidant which metabolises toxic lipid peroxides), exposure to subthreshold occupational limits of NO, (2-3 ppm) for 5 hours did not decrease lung function at all but after 11 hours of exposure, the alveolar permeability had decreased 22070 and after 24 hours of exposure the serum glutathione peroxidase activity had decreased 14070. 111 Inhalation of 5 ppm for 15 minutes by adults caused significant reduction in P,o, and diffusion capacity for CO and an increment in airways resistance. 11' .113 Exposure of dogs for one hour to high concentrations of NO, (200 or 400 ppm) damaged lung epithelial and endothelial cells and allowed albumin to accumulate in the alveoli and focal pulmonary oedema to be detected on microscopy. Moreover, functional residual capacity was reduced by 15070. These physiological abnormalities were most noticeable two days after exposure but had regressed by 14 days. 114 Exposure of rats to 50 ppm NO, for 30 minutes and to 100 ppm NO, for 5-15 minutes caused significant increases in lung weight measured 24 hours after exposure, 115 presumably due to pulmonary oedema. Exposure of rats to 50 ppm NO, for five hours a day for seven days caused structural changes in the major bronchi and terminal bronchioles. 116 Loss of cilia and disintegration of the epithelium were evident on day 1, worse in the major bronchi. Diminution of luminal diameter and the presence of mural inflammation were more conspicuous in the terminal bronchioles.
The bronchoconstrictor effect of NO, in humans has been disputed. A concentration of 2 ppm did not alter the bronchial reactivity of normals, nor did 0.5 ppm in asthmatics. 117 However, other investigators have shown that 0.3 ppm potentiated exercise-induced bronchospasm and airway hyperreactivity after cold air provocation in asthmatic subjects 118 and a 10070 reduction in FEV 1 in patients with chronic obstructive pulmonary disease. 119 Nitrogen dioxide may react with secondary amines to yield nitrosamines, which are carcinogenic in laboratory animals. 1211 This is a concern but not a new one. Endogenous production of nitrosamines in humans has been demonstrated. 121 The sources of nitrate are dietary and endogenous synthesis. Other cells besides endothelial cells consume L-arginine to produce nitric oxide and nitrates. 122 Nitric oxide is also produced by neutrophils, brain cells and platelets. 1 Relatively few studies have been conducted to investigate the toxic effects of NO alone. Exposure of rats up to 1500 ppm NO for 15 minutes or 1000 ppm for 30 minutes produced no demonstrable increases in lung weight nor any detectable histopathologic changes 24 hours after exposure. 11< Lambs which breathed 80 ppm for one to three hours did not sustain any microscopic damage nor accumulate water in the lungs. 12. 1 Rabbits exposed to a mixture of 43 ppm NO and 3.6 ppm NO, for six days did not sustain any morphological damage to the lungs. 124 Studies in humans are limited but short-term inhalation (15 minutes) of small concentrations (30 ppm) of pure NO by adults did not cause serious problems; P"o, did not alter with 15 ppm but decreased 7-8 mmHg with 15-30 ppm; diffusion capacity for CO did not decrease with 20-39 ppm. However, airway resistance increased above 20 ppm. 112.11'
b. Pulmonary Vasodilator
Although nitrovasodilators have a greater influence on the venous circulation than the arterial circulation, they act on all regions of the circulation. One of the major gaps in clinical therapeutics is the lack of an agent which can influence the pulmonary circulation without causing a simultaneous detrimental effect on the systemic circulation. The properties of gaseous NO may enable it to be used as a selective pulmonary vasodilator. As a gas it could gain access to pulmonary blood vessels from the abluminal surface adjacent to the airways without being exposed to blood, thereby avoiding massive methaemoglobinaemia and systemic hypotension ( Figure I) . Moreover, with gaseous administration, ventilation-perfusion matching may be improved, in contrast to intravenous vasodilators which may increase perfusion to unventilated lung. The little amount which does gain access to the circulation become bound to haemoglobin and thus inactivated.
The role of EDRF in the control of pulmonary vascular resistance appears to be established in utero. EDRF activity is present in the guinea pig pulmonary artery and descending aorta at birth. 12< In lategestation foetal lambs the infusion of a selective inhibitor of EDRF production, nitro-L-arginine, decreased pulmonary blood flow and increased pulmonary artery pressure, both significantly. Moreover, the expected rise in pulmonary blood flow after delivery by caesarean section was reduced with nitro-L-arginine. These observations suggest that EDRF is present in the foetal lung and contributes to post delivery changes in the pulmonary circulation. 126 Further evidence for the role of EDRF in the control of resting pulmonary vascular tone is the observation that nitro-L-arginine caused an increase in pulmonary artery pressure in young lambs. 127 It is well known that the presence of hypoxia is important in the generation of pulmonary hypertension. The mechanism has been recently determined. Chronic exposure to hypoxia in rats led to pulmonary hypertension and to a loss of EDRF activity in the pulmonary vessels, which recovered on return to a normoxic environment. 1" In foetal lambs, the presence of hypoxia depressed the basal and ACHstimulated production of cyclic GMP. In addition, relaxation of the pulmonary vasculature, which was dependent upon the endothelium, was decreased during hypoxia and restored with re-oxygenation. 129 Similar observations have been made in experiments with the pulmonary arteries of rats.1111 These observations support the concepts that oxygen modulates the production of EDRF in foetal pulmonary arteries and that pulmonary hypertension is due to a lack of EDRF. Indeed, administration of the NO precursor L-arginine restored endothelium dependent relaxation activity in the pulmonary circulation of chronically hypoxic rats 1111 whereas administration of nitro-L-arginine (an inhibitor of EDRF production) caused vasoconstriction in rats which had been exposed to chronic hypoxia and then returned to normoxia. l12 The efficacy of NO in the treatment of pulmonary hypertension has been established in animal studies, in human newborns with persistent pulmonary hypertension, in children with pulmonary hypertension after cardiac surgery, in adults with idiopathic pulmonary hypertension and in adults with pulmonary hypertension secondary to chronic obstructive lung disease or adult respiratory distress syndrome (ARDS).
In lambs with pulmonary hypertension induced by hypoxaemia or by the pulmonary vasoconstrictor thromboxane endoperoxide analogue U46619, spontaneous inhalation of 40-80 ppm NO reversed the pulmonary vasoconstriction within three minutes. Tolerance was not observed over one hour but pulmonary hypertension resumed within three to six minutes after cessation of NO. In contrast, pulmonary and systemic parameters were unaltered by NO in normal lambs. 121 In the same laboratory, inhalation of 40-80 ppm or 180 ppm NO ameliorated the rise in Anaesrhe5iu and Intensive Care, Vol. 21, Nu. 6, December, 1993 pulmonary artery pressure and resistance usually observed after the injection of protamine into heparinised lambs, a procedure which releases endogenous thromboxane. 13J It was also observed that pre-treatment of the lambs with indomethacin, a cyclooxygenase inhibitor, before the infusion of U46619 did not reduce the vasodilatory effect of NO. The authors concluded that the vasodilatory effect of NO was independent of cyclo-oxygenase products such as prostacyclin. Additional studies in the same laboratory with mechanically ventilated newborn lambs have reported that pulmonary hypertension, induced by hypoxia or acidosis, was reversed with 80 ppm NO without reduction in systemic blood pressure or resistance. Treatment with NO also increased the leftto-right ductal blood flow. 134 In mechanically ventilated dogs, administration of 40 or 80 ppm NO prevented the pulmonary hypertension otherwise observed during hypoxia. 135 Administration of 80 ppm NO for 30 minutes in six newborn infants resulted in a marked increase in postductal oxygenation. All six infants, three with meconium aspiration, had a clinical diagnosis of persistent pulmonary hypertension of the newborn (PPHN), severe post-ductal hypoxaemia, right-to-Ieft shunting across the ductus arteriosus, interventricular septal flattening and tricuspid regurgitation in the absence of structural defects. This observation suggested that NO reduced pulmonary hypertension. Neither systemic hypotension nor methaemoglobinaemia were observed. 136 More prolonged administration (up to 24 hours) of lower dose NO (6-20 ppm) to nine newborn infants with PPHN also effectively improved oxygenation without causing systemic hypotension or methaemoglobinaemia.])7 These infants, five with meconium aspiration and/or sepsis and four with idiopathic PPHN, fulfilled criteria for commencement of extracorporeal membrane oxygenation (ECMO). Six of the infants who were treated with NO for 24 hours recovered without the need for ECMO and were weaned from ventilation and supplemental oxygen therapy within one month and showed no evidence of chronic lung disease. The remaining three infants were treated with ECMO after receiving NO for four hours but their outcomes are unknown.
In adult humans with idiopathic pulmonary hypertension, inhalation of NO 40 ppm in air for periods of five minutes interspersed with similar periods breathing air, produced significant reductions in pulmonary vascular resistance during NO treatment and return to baseline on resumption to air inhalation. At the same time systemic vascular resistance was not depressed. In contrast, an infusion of prostacyclin (PGI 2) at 24 {tg/hr produced significant reductions in Anaesthesia and Intensive Care, Vol. 21. No. 6. December, 1993 both pulmonary and systemic vascular resistance, the former to a similar degree as NO. In another ten adult patients with heart disease (unspecified) and another ten healthy adult volunteers, inhalation of NO did not change systemic vascular resistance but lowered pulmonary vascular resistance in the cardiac patients. NO was judged to be a selective and effective pulmonary vasodilator. 13R Administration of NO has been found to reduce pulmonary hypertension associated with severe adult respiratory distress syndrome (ARDS). Nine patients with severe ARDS were treated with NO 18 and 36 ppm for 30 minutes and with prostacyclin 4 ng/kg/min. 139 The pulmonary artery pressure (PAP) was reduced significantly from a mean of 37 mmHg to 30 mmHg with both NO at 18 ppm and with prostacyclin. However, systemic mean arterial pressure (MAP) fell significantly with prostacyclin but not with NO. Intrapulmonary shunting (Qs/Qt) decreased and P,,02/Fi02 ratio increased with NO, whereas the reverse occurred with prostacyclin. It was concluded that NO, in contrast to prostacyclin, is a selective pulmonary vasodilator and improves VlQ matching (by redistributing pulmonary blood flow away from nonventilated to ventilated regions. In another study of six patients with ARDS, some members of the same research team conducted a similar study with 18 and 36 ppm NO and with PGI 2 each for 30 minutes. PAP fell from a mean of 35 mmHg to 28 mmHg with NO 18 ppm while pulmonary vascular resistance decreased significantly with both concentrations of NO. A significant reduction in right ventricular ejection fraction however was only observed with 36 ppm NO. PGI I had no significant haemodynamic effect. 140 In a study in five mechanically ventilated patients with sepsis and ARDS, administration of 20 and 40 ppm NO reduced mean PAP from 31 mmHg to 27 mmHg while small increments were observed in P,,02 and MAP and small reductions in cardiac output and Qs/Qt. 141 Since publication of these results, an additional four patients have entered the study, without changing the mean decrease in mean PAP of 3-4 mmHg.142 Administration of 12-18 ppm NO in ten patients with ARDS decreased mean systolic pulmonary artery pressure from 38 to 33.6 mmHg while infusion of L-arginine had no effect. 143 Nitric oxide has been utilised to treat pulmonary hypertension associated with chronic obstructive airways disease (COAD). Inhalation of 40 ppm NO by six patients prompted a decrease in the mean PAP from 29 to 24 mmHg with no other significant haemodynamic or respiratory changes. 144 Inhalation of 15 ppm NO in air by eight subjects caused a significant decrease in pulmonary vascular resistance without 1. TIBBALLS ET AL. changes in cardiac output, systemic vascular resistance and VlQ matching. It was suggested that the absence of alteration in gas exchange could have been due to a bronchodilator effect. 14< Pulmonary artery rings harvested from patients undergoing heart-lung transplantation for end-stage COAD did not relax as well in response to acetylcholine and adenosine diphosphate as did control arteries obtained from patients with lung carcinomas but free of COAD. Moreover, inhibition of EDRF synthesis with L-NMMA increased the tension generated by control arteries but not those from patients with COAD. It was concluded that endothelium-dependent pulmonary artery relaxation (in vitro) is impaired in arteries from patients with end-stage COAD and may contribute to the development of pulmonary hypertension in chronic hypoxic lung disease. 146 Further experiments confirmed that endothelium-dependent (acetylcholine) relaxation was significantly reduced in pulmonary artery rings in patients with COAD. In addition, administration of L-arginine, the substrate for NO synthesis, failed to rectify acetylcholine relaxation induced by L-NMMA. The investigators proposed that the impairment of pulmonary endothelium-dependent relaxation in chronic hypoxic lung disease must be within the biosynthetic pathway of L-arginine to NO, possibly involving the enzyme NO-synthase. 14' Inhalation of NO in 0, for 30 minutes during cardiac catheterisation decreased pulmonary artery pressure in children with congenital heart disease. 14X In ten children, the mean pulmonary artery pressure decreased from 4S±19 to 40±14 mmHg after inhalation of SO ppm NO in 21-30070 0, and to 37 ± 11 mmHg in 90070 0,. Less pronounced reductions in pulmonary artery pressure were observed with smaller amounts of NO (20-40 ppm) or with 90070 O 2 alone. Aortic pressure did not decrease and methaemoglobin levels did not rise during the 30 minutes of treatment. In six of the ten patients with intracardiac shunting, SO ppm NO in 90070 0, increased the pulmonary to systemic blood flow ratio from 2.0±0.S to 4.7 ±2.5.
Additional applications of NO in infants and children with pulmonary hypertension, congenital heart lesions and cardiomyopathy are discussed by the author in this issue of the journal. 14') 
c. Bronchodilator
Just as the endothelium has been shown to be vital in the regulation of luminal diameter of blood vessels, the epithelium has been shown to be vital in the regulation of the lumen of the airways. Release of relaxing factors from epithelial cells may contribute to the regulation of bronchomotor tone. It has been ,uggested that reduced release of epithelium-derived relaxing factor(s) may help to explain bronchial hyperreactivity secondary to epithelial damage. ISO Circumstantial evidence suggests that NO may be intimately involved.
The smoke of cigarettes (containing NO 400-1000 ppm) induces an increase in lung guanylate cyclase activity and cyclic GMP. 1 '1
Nitrovasodilators are known to cause relaxation of bovine bronchial smooth muscle strips. 152, 151 NO gas activated guanylate cyclase and increased guanosine 3 1 -5 I-cyclic monophosphate levels in various tissue preparations, including bovine tracheal smooth muscle. 154 Few in vivo studies have been conducted.
Administration of 300 ppm NO to mechanically ventilated guinea pigs significantly decreased airway resistance. Moreover, when bronchoconstriction was induced with methacholine, resistance could be reversed in a dose-related, rapid, consistent and reversible fashion with 5-300 ppm NO. A concentration of 15 ± 2 ppm reduced resistance by 50070. Tolerance did not develop over one hour with 100 ppm NO and methaemoglobin did not increase. 15< This study also investigated the effects of an NO-releasing compound, S-nitroso-N-acetylpenicillamine, which as an aerosol induced a rapid and profound decrease in resistance from 0.453 to 0.2S7 cmH,O/ml.sec in metacholinebronchoconstricted guinea pigs. In six asthmatic adults, inhalation of SO ppm NO for ten minutes significantly improved airway conductance but to a lesser degree than salbutamol. lOO 
PRACTICAL NITRIC OXIDE THERAPY
At present NO therapy has been confined to patients with severe pulmonary hypertension in centres equipped with sophisticated investigational cardiorespiratory monitoring devices. However gaseous NO may soon enter widespread use in intensive care units and related areas for the acute treatment of pulmonary hypertension. To ensure the safety of the patient and staff, a number of practical guidelines should be followed: I. A pure preparation of NO in N, from a reputable gas supply company should be utilised. Higher oxides of nitrogen should not contaminate the mixture. However, preparations cannot be 100070 pure and in any case, NO is thermodynamically unstable at room temperature and the compressed gas slowly undergoes disproportionation to form N,Ol and NO,. 2. Preparations of NO in N, of 200 to 1000 ppm facilitate administration of a range of therapy without exposing the patient to a hypoxic gas mixture. A patient who requires near 100070 0, and 20 ppm NO may be treated with a mixture of 100070
Anaesthesia and Inlensive Care, Vol. 21, ,Vo. 6, Decemher, 1993 0, and 1000 ppm NO in N, which results in an Flo, of 0.98. However, the use of NO in a high concentration necessitates the use of a low flow of NO which may be difficult to manage. Lesses concentrations are easier to regulate and better suited to patients who do not require a high Flo,. The therapeutic range of NO is approximately 5-40 ppm.
3. The period of mixing of NO with 0, should be kept to a minimum. NO should be introduced into a Douglas bag or similiar and mixed with air or 0, immediately before spontaneous respiration. If used during mechanical ventilation, NO should be introduced into the ventilator circuit, preferably into the inspiratory limb. Methods of administration are discussed in further detail by the author in this issue. 157 
Leaks into the immediate atmosphere should be
prevented. Circuits should be airtight and cuffed endotracheal tubes should be employed wherever possible. Until evidence is presented to the contrary, exhaled and excess gas should be scavenged and vented to the external atmosphere. Gas cylinders should be serviced regularly and stored in safe areas according to occupational and health safety standards. There may be a requirement to maintain self-contained breathing apparatus on site. 5. The inspired NO concentration should be accurately monitored as should the NO, concentration in the circuit. Chemiluminescence monitors which can measure all oxides of nitrogen are expensive ($15,000-$30,000). Electrochemical detectors of NO is cheaper and equally sensitive and accurate 158 but not able to detect NOz, a major disadvantage. An additional electrochemical detection for NO, must be used. There may be a requirement to monitor NO and NO, concentrations in the immediate environment. 6. Methaemoglobin levels in the patient should be monitored.
SUMMARY
Nitric oxide is widely distributed in the body. It has an important role in the regulation of the circulation and as yet, ill-defined roles in nervous and immune systems. It is derived from L-arginine from a reaction catalysed by a constitutive intracellular enzyme, nitric oxide synthase. It is recognised as the endogenous nitrovasodilator whose action is mimicked by all exogenous nitrovasodilators. After production in the vascular endothelial cell, it diffuses to the smooth muscle cell where it activates the enzyme guanylate cyclase which leads to an increase in cyclic GMP and Anaesthesia and Intensive Care. Vol. 21 . No. 6. December. 1993 thence to muscle relaxation. The duration of its action is brief, a few seconds.
Disorders of NO metabolism underlie many disease states including endotoxic shock in which prolonged production of nitric oxide may be induced by cytokines. Deficiencies in endogenous production may account for hypertension in various disease states including atherosclerosis and chronic renal failure.
NO therapy been used experimentally to successfully treat idiopathic pulmonary hypertension and pulmonary hypertension associated with cardiac and respiratory diseases. However, the long-term benefits have yet to be studied.
Administration of NO requires the use of a device to monitor the concentrations of both NO and of NO,. The latter is a noxious agent and a time-related product of the reaction between NO and 0, and is a possible contaminant of preparations of NO.
Precautions must be taken to prevent contamination of the work-place atmosphere with NO and NO,. These include gas scavenging and the use of a leakfree system for spontaneous and mechanical ventilation.
Using NO in its gaseous form, clinicians have at long last been provided with the means to treat pulmonary hypertension without adversely causing systemic hypotension. The therapy is most suited to short-term use in mechanically ventilated patients. Safe practical long-term NO therapy must await the development of agents which release NO from aerosol preparations.
